SUPN

SUPN

USD

Supernus Pharmaceuticals Inc. Common Stock

$57.000+1.570 (2.832%)

即時價格

Healthcare
Drug Manufacturers - Specialty & Generic
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$55.430

最高

$57.400

最低

$54.610

交易量

4.00M

公司基本面

市值

3.2B

行業

Drug Manufacturers - Specialty & Generic

國家

United States

交易統計

平均交易量

0.82M

交易所

NGM

貨幣

USD

52週範圍

最低 $29.16當前 $57.000最高 $57.65

相關新聞

Analyst Upgrades

B of A Securities Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces Price Target of $65

B of A Securities analyst Pavan Patel initiates coverage on Supernus Pharmaceuticals with a Buy rating and announces Price Target of $65.

查看更多
B of A Securities Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces Price Target of $65
Analyst Upgrades

TD Cowen Maintains Buy on Supernus Pharmaceuticals, Raises Price Target to $60

TD Cowen analyst Stacy Ku maintains Supernus Pharmaceuticals with a Buy and raises the price target from $45 to $60.

查看更多
TD Cowen Maintains Buy on Supernus Pharmaceuticals, Raises Price Target to $60
GlobeNewswire

Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

ROCKVILLE, Md., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

查看更多
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
Analyst Upgrades

Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight, Raises Price Target to $65

Piper Sandler analyst David Amsellem upgrades Supernus Pharmaceuticals from Neutral to Overweight and raises the price target from $40 to $65.

查看更多
Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight, Raises Price Target to $65